Chinese COVID-19 candidate vaccine arrives in Brazil

Wednesday, 22 Jul, 2020

Russia claims to have created a safe vaccine against the novel coronavirus, following the completion of clinical trials by the Sechenov University (Moscow, Russia) of a COVID-19 vaccine candidate developed by the Gamalei Institute of Epidemiology and Microbiology (Moscow, Russia).

It will be administered to doctors and other health workers who volunteer for the program across six states in Brazil, one of the countries hit hardest by the pandemic. "This is an important step in evaluating this early-stage experimental vaccine and phase 3 trials are now underway", said study researcher Feng-Cai Zhu, Jiangsu Provincial Center for Disease Control and Prevention in China. The data included in the paper covered only the first 56 days of the trial. CanSino's planned trial in Canada has included groups of participants that will receive a second shot.

The Chinese study involved 508 participants aged 18-83, and reported antibodies in 85 percent and T-cell responses in 90 percent of participants.

The vaccine candidate has passed Phase 1 and Phase 2 clinical trials.

According to the researchers, 508 participants took part in the trial of the new vaccine.

On the same occasion Tuesday, Penny Lukito, head of the Food and Drug Monitoring Agency, said her agency will monitor the process of clinical trial testing for the vaccine candidate until it is completed.

"A vaccine that can stop COVID-19", Fuller wrote, "will ideally induce protective immunity after only a single immunization, avoid immune responses that could exacerbate virus-induced pathology, be amenable to rapid and cost-effective scale-up and manufacturing, and be capable of inducing immunity in all populations including the elderly who typically respond poorly to vaccines".

Both found production of neutralising antibodies and T-cell responses in the majority of test subjects, with side effects including mild fatigue, headaches and pains treatable by common painkillers. 72% of the patients received the medium dose, while 74% received the lower dose.

There were no serious adverse events associated with the vaccine.

"All of these three things have to happen and come together before we can start seeing large numbers of people vaccinated", Gilbert said. "A successful vaccine against SARS-CoV-2 could be used to prevent infection, disease and death in the whole population, with high risk populations such as hospital workers and older adults prioritised to receive vaccination".